Results 21 to 30 of about 760 (154)

Synergistic Effects of Sulopenem in Combination with Cefuroxime or Durlobactam against Mycobacterium abscessus

mBio, 2023
ABSTRACT Mycobacterium abscessus ( Mab ) affects patients with immunosuppression, Cystic Fibrosis (CF), or underlying structural lung diseases. Additionally, Mab poses clinical challenges due to its resistance to multiple ...
Khalid M. Dousa, Eunjeong Shin, Sebastian G. Kurz, Mark Plummer, Mary Nantongo, Christopher R. Bethel, Magdalena A. Taracila, David C. Nguyen, Barry N. Kreiswith, Charles L. Daley, Kenneth E. Remy, Steven M. Holland, Robert A. Bonomo   +12 more
openaire   +4 more sources

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii

Antimicrobial Agents and Chemotherapy, 2023
ABSTRACTAcinetobacter baumannii-calcoaceticuscomplex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused byAcinetobacter, including multidrug- and carbapenem ...
Samir H. Moussa, Adam B. Shapiro, Sarah M. McLeod, Ramkumar Iyer, Nicole M. Carter, Yu-Kuo Tsai, L. Kristopher Siu, Alita A. Miller   +7 more
openaire   +2 more sources

in a critically ill burn patient: clinical challenges and molecular characterization [PDF]

, 2023
Background Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with high mortality rates. The optimal treatment regimen for CRAB has not been defined.
Riccardi, Niccolò, Federica Limongi, Tiseo, Giusy, Nicastro, Manuela, Simona Barnini, Valentina Galfo, Barnini, Simona, Giordano, Cesira, Galfo, Valentina, Niccolò Riccardi, Limongi, Federica, Manuela Nicastro, Giusy Tiseo, Leonildi, Alessandro, Cesira Giordano, Alessandro Leonildi, Marco Falcone, Falcone, Marco   +17 more
core   +1 more source

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects [PDF]

, 2019
Sulbactam-durlobactam is being developed for the treatment of infections caused by , including those caused by multidrug- and carbapenem-resistant isolates.
Mamikonyan, Grigor, Preston, Richard A, Isaacs, Robin, Stone, Emily, O'Donnell, John   +4 more
core   +1 more source

Pharmacokinetics of sulbactam-durlobactam in patients with <i>Acinetobacter baumannii</i> ventriculitis: a report of two cases. [PDF]

Antimicrob Agents Chemother
ABSTRACT Two adult patients with ventriculitis due to Acinetobacter baumannii were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by
Pouya N, Finch NA, Granillo A, Bhimraj A, Tam VH, Miller WR.   +5 more
europepmc   +4 more sources

Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. [PDF]

Antimicrob Agents Chemother
Infections caused by carbapenem-resistant complex (ABC) are associated with high mortality rates and limited treatment options. This study aims to evaluate the activity of clinically utilized antimicrobials against a contemporary collection of ABC ...
Buyukyanbolu E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Fisher M, Gialanella P, Hand J, Harrington AT, Humphries RM, Huse H, Hamilton-Seth R, Hankins JD, Kufel WD, Riddell SW, Marino J, Westblade LF, Mochon AB, Narayanan N, Kirn TJ, Pierce VM, Potula R, Tekle T, Simner PJ, Tibbetts RJ, Vu C, Abbo LM, Martinez O, Dumm RE, Nicolau DP, Asempa TE, Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group.   +33 more
europepmc   +2 more sources

How to treat severe Acinetobacter baumannii infections. [PDF]

, 2023
20.500.12530/87858To update the management of severe Acinetobacter baumannii infections (ABI), particularly those caused by multi-resistant isolates. The in vitro activity of the various antimicrobial agents potentially helpful in treating ABI is highly ...
Muñoz, Patricia, Bouza, Emilio, Burillo, Almudena   +2 more
core   +1 more source

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Clinical Infectious Diseases, 2023
Abstract Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of
Watkins, Richard R, Bonomo, Robert A
openaire   +2 more sources

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory [PDF]

, 2023
The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem ...
Carmella Russo, Romney Humphries
core   +1 more source

Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant <i>Acinetobacter baumannii</i> strains. [PDF]

JAC Antimicrob Resist
Abstract Background Acinetobacter baumannii is a bacterial pathogen frequently implicated in healthcare-associated infections, with limited effective treatment options due to widespread antibiotic resistance.
Halim J, Bouzo J, Carabetta VJ.
europepmc   +3 more sources